Joe Anderson

Spear’s Review

Joe Anderson has over 25 years’ experience in the life sciences industry, with a track record of generating investment returns.

He was partner at Abingworth LLP for 12 years (where he led venture-capital style investments in public companies), founded and managed public equities funds, was a director of Algeta (acquired by Bayer AG for $2.9 billion), Amarin plc, Cytos (merged with Kuros) and Epigenomics AG, CEO of Arix Bioscience and is currently a partner at Sofinnova. 

Anderson began his career at the Ciba (now Novartis) Foundation, before joining The Wellcome Trust in 1990 where he became head of strategy. He then moved to the City of London as a pharmaceuticals analyst at Dresdner Kleinwort Benson.